Search results
Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy By Investing.com
Investing.com· 5 days agoSanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
AstraZeneca, Sanofi Bolt Higher On Quarterly Beats, But Bristol Myers Dives
Investor's Business Daily· 5 days agoThe Cambridge U.K.-based drugmaker reported almost $5.11 billion in sales of its cancer drugs. Sales...
Bankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rules
Reuters· 5 days agoMallinckrodt's bankruptcy permitted the drug company to end a perpetual royalty agreement with ...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 4 days agoThe first-quarter 2024 earnings season picked up pace this week, with Merck MRK, Sanofi SNY,...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Morningstar· 6 days agoSanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent ...
Sanofi Q1 profit slips on generic competition, forex effects
Reuters via Yahoo Finance· 6 days agoApril 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug ...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 5 days agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Sanofi: Q1 Earnings Snapshot
San Francisco Chronicle· 5 days agoPARIS (AP) — PARIS (AP) — Sanofi (SNY) on Thursday reported first-quarter net income...
Sanofi Q1 profit slips on generic competition, forex effects
KFGO· 5 days agoBy Ludwig Burger (Reuters) -Sanofi reported on Thursday that its first-quarter operating income...
SASYn | Sanofi SA Share Price - Investing.com NG
Investing.com· 6 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
